Scholar Rock eyes phase 3 after confirming effects of SMA drug

Scholar Rock has reported 12-month data on spinal muscular atrophy (SMA) candidate apitegromab. The readout is in line with the six-month data drop that sent Scholar Rock’s stock price soaring in October, teeing the biotech up to move into a pivotal study by the end of the year.